Asunto(s)
Autoanticuerpos/inmunología , Epítopos/inmunología , Cabello/anomalías , Enfermedad de Hirschsprung/inmunología , Síndromes de Inmunodeficiencia/inmunología , Osteocondrodisplasias/congénito , Poliendocrinopatías Autoinmunes/inmunología , Adulto , Anciano , Diversidad de Anticuerpos , Femenino , Cabello/inmunología , Enfermedad de Hirschsprung/genética , Humanos , Síndromes de Inmunodeficiencia/genética , Masculino , Persona de Mediana Edad , Osteocondrodisplasias/genética , Osteocondrodisplasias/inmunología , Poliendocrinopatías Autoinmunes/genética , Enfermedades de Inmunodeficiencia Primaria , Análisis por Matrices de Proteínas , ARN Largo no Codificante/genética , Adulto JovenAsunto(s)
Cabello/anomalías , Enfermedad de Hirschsprung/diagnóstico , Enfermedad de Hirschsprung/inmunología , Inmunidad , Síndromes de Inmunodeficiencia/diagnóstico , Síndromes de Inmunodeficiencia/inmunología , Osteocondrodisplasias/congénito , Fenotipo , Adulto , Biomarcadores , Niño , Estudios de Cohortes , Finlandia , Cabello/inmunología , Humanos , Memoria Inmunológica , Inmunofenotipificación , Subgrupos Linfocitarios/inmunología , Subgrupos Linfocitarios/metabolismo , Osteocondrodisplasias/diagnóstico , Osteocondrodisplasias/inmunología , Enfermedades de Inmunodeficiencia PrimariaRESUMEN
BACKGROUND: Cartilage-hair hypoplasia (CHH) is an autosomal recessive chondrodysplasia caused by RMRP (RNA component of mitochondrial RNA processing endoribonuclease) gene mutations. Manifestations include short stature, variable immunodeficiency, anaemia and increased risk of malignancies, all of which have been described also in telomere biology disorders. RMRP interacts with the telomerase RT (TERT) subunit, but the influence of RMRP mutations on telomere length is unknown. We measured relative telomere length (RTL) in patients with CHH, their first-degree relatives and healthy controls and correlated RTL with clinical and laboratory features. METHODS: The study cohort included 48 patients with CHH with homozygous (n=36) or compound heterozygous RMRP mutations (median age 38.2â years, range 6.0-70.8â years), 86 relatives (74 with a heterozygous RMRP mutation) and 94 unrelated healthy controls. We extracted DNA from peripheral blood, sequenced the RMRP gene and measured RTL by qPCR. RESULTS: Compared with age-matched and sex-matched healthy controls, median RTL was significantly shorter in patients with CHH (n=40 pairs, 1.05 vs 1.21, p=0.017), but not in mutation carriers (n=48 pairs, 1.16 vs 1.10, p=0.224). RTL correlated significantly with age in RMRP mutation carriers (r=-0.482, p<0.001) and non-carriers (r=-0.498, p<0.001), but not in patients (r=-0.236, p=0.107). In particular children (<18â years) with CHH had shorter telomeres than controls (median RTL 1.12 vs 1.26, p=0.008). In patients with CHH, RTL showed no correlation with genotype, clinical or laboratory characteristics. CONCLUSIONS: Telomere length was decreased in children with CHH. We found no correlation between RTL and clinical or laboratory parameters.
Asunto(s)
Cabello/anomalías , Enfermedad de Hirschsprung/genética , Síndromes de Inmunodeficiencia/genética , Osteocondrodisplasias/congénito , Homeostasis del Telómero , Adolescente , Adulto , Anciano , Estudios de Casos y Controles , Niño , Endorribonucleasas/genética , Femenino , Heterocigoto , Humanos , Masculino , Persona de Mediana Edad , Morbilidad , Mutación/genética , Osteocondrodisplasias/genética , Enfermedades de Inmunodeficiencia Primaria , Adulto JovenAsunto(s)
Alelos , Efecto Fundador , Cabello/anomalías , Enfermedad de Hirschsprung/diagnóstico , Enfermedad de Hirschsprung/genética , Síndromes de Inmunodeficiencia/diagnóstico , Síndromes de Inmunodeficiencia/genética , Mutación , Osteocondrodisplasias/congénito , ARN Largo no Codificante/genética , Adulto , Consanguinidad , Análisis Mutacional de ADN , Finlandia , Humanos , Masculino , Osteocondrodisplasias/diagnóstico , Osteocondrodisplasias/genética , Pakistán , Linaje , Fenotipo , Enfermedades de Inmunodeficiencia Primaria , RadiografíaAsunto(s)
Bronquiectasia/etiología , Cabello/anomalías , Enfermedad de Hirschsprung/complicaciones , Síndromes de Inmunodeficiencia/complicaciones , Osteocondrodisplasias/congénito , Adolescente , Adulto , Anciano , Bronquiectasia/diagnóstico , Bronquiectasia/epidemiología , Estudios de Cohortes , Femenino , Finlandia , Humanos , Masculino , Persona de Mediana Edad , Osteocondrodisplasias/complicaciones , Prevalencia , Enfermedades de Inmunodeficiencia Primaria , Adulto JovenRESUMEN
UNLABELLED: Hyperimmunoglobulinemia D syndrome (HIDS) is an autoinflammatory disorder that is caused by mevalonate kinase deficiency (MKD). Recent advances in the pathogenesis of MKD, including the proposed mechanisms of inflammasome activation, provide the basis for the development of new treatment modalities. So far, feedback on the treatment of HIDS with biological medicines has come from case reports with limited numbers of patients. In this review, we summarize the data that is currently available on the treatment of HIDS in children, with the emphasis on new therapies, and present three Finnish pediatric cases treated with anakinra. Case reports have been published on 33 pediatric HIDS patients who have been treated with biological medicines, and in some cases, they were treated with more than one drug. Of these patients, 21 were treated with anakinra and 16 with etanercept, resulting in complete or partial responses in 90 and 50% of cases, respectively. A further five patients were treated with canakinumab, with complete or partial responses. CONCLUSION: The accumulating evidence on the efficacy and safety of biological drugs in pediatric HIDS suggests that the anti-interleukin-1 agent anakinra is the drug of choice for HIDS in children. WHAT IS KNOWN: ⢠Various biologic drugs have been tried for the treatment of HIDS. What is New: ⢠Based on the 90% response rate, anakinra seems to be the drug of choice for HIDS in children.